Reviewed October 25, 2026
Is Sermorelin Legal? What the FDA Record Shows
Sermorelin was not on the advisory committee's July 2026 list. Almost nobody selling it will tell you what that means, so here is the record, with the dates on it.
The short answer, in four dated lines
- July 2026 advisory review
- Not among the seven peptides reviewed
- 503A category 1
- Not listed (FDA list updated May 14, 2026)
- 503A category 2
- Not listed (same FDA list)
- 21 CFR 216.23
- Not named (checked October 25, 2026)
Absence from these lists is not a prohibition. It means no advisory committee has taken a position on sermorelin and the federal compounding list does not name it. That changes who can help you and what you should ask.
What sermorelin is, in one paragraph
Sermorelin is a 29-amino-acid fragment of growth-hormone-releasing hormone, usually written GHRH 1-29. It works upstream of growth hormone rather than as growth hormone: it signals the patient's own pituitary to release growth hormone in pulses, where recombinant growth hormone introduces the hormone itself. The mechanism is well described in the literature and the adult safety profile has been under long-running pharmacologic review.
That is a description of how the molecule behaves. It is not a claim that it helps anyone with anything. Those are different sentences, and clinics blur them.
Three facts, each with a date
First: the July 2026 review did not include it. The committee spent two days on seven peptides, recommending six of them continue in the 503A bulks list process and declining to recommend the seventh. Sermorelin was not on the agenda. If a clinic tells you the committee approved sermorelin, the clinic is describing a meeting that did not happen.
Second: it is absent from the FDA's two named 503A categories. The category 1 list, updated May 14, 2026, covers bulk substances FDA is still evaluating and does not intend to act against compounders for using, provided the guidance conditions are met. Sermorelin is not on it. The category 2 list, for substances FDA has identified as raising significant safety concerns, does not name it either. For a patient, the practical consequence is the first list, not the second: the non-enforcement policy FDA describes for category 1 substances does not reach sermorelin.
Third: it is not named in 21 CFR 216.23. That regulation is the federal bulks list itself. We checked the current text on October 25, 2026 and sermorelin does not appear in it.
Read those three together and you have the honest shape of the thing. No committee position, no category 1 cover, no name in the regulation. Not a prohibition. A gap.
Why "is it legal" has no yes-or-no answer
For peptides, access is not one switch. It runs through the federal status of the substance, whether a compounding pathway applies to your situation, what your state's pharmacy and medical boards allow, and whether a licensed clinician has evaluated you and written a prescription. A flat yes or no skips at least three of those, and the missing three are the ones that decide whether you end up with a legitimate prescription or a vial in a padded envelope.
This is where sermorelin differs from the peptides that got headlines in July. BPC-157, KPV, TB-500, MOTS-C, Semax and Epitalon all came out of that meeting with a committee recommendation attached, whether or not you agree with it. Sermorelin has no such recommendation to point at. The absence cuts both ways: nobody can cite a favourable vote, and nobody can cite an unfavourable one.
What to ask instead of "is it legal"
Ask about the monitoring. Growth-hormone-axis compounds are not a set-and-forget prescription. A clinician operating to a defensible standard will draw an IGF-1 baseline before writing anything, and will tell you who reviews the repeat labs and at what interval. If the answer is that labs are optional, you have learned more from that answer than from any regulatory summary.
Ask which pharmacy, by name, and in which state it holds a licence. Under section 503A the compounding pharmacy and the prescriber's relationship to it matter. A clinic that cannot name the pharmacy is not describing a supply chain you can check.
Ask what would stop the protocol. Out-of-range IGF-1, an adverse event, no measurable change at a defined checkpoint, a new contraindication. A clinician who cannot describe stop criteria has not thought about them, and the person left defending that position will be you.
Ask for the exact product, not the brand name. Sermorelin describes a sequence. It does not describe a formulation, a concentration, a sterile process or a pharmacy. Two clinics quoting the same word can be selling two different things.
What is still unclear
We will not pretend the picture is cleaner than it is. The FDA has an active process for evaluating nominated bulk substances, and the committee has said it intends to consult further on peptide nominations. A future list update could name sermorelin. If it does, this page changes and the date at the top changes with it.
Until then the position is: not reviewed, not listed in either named category, not in the regulation. Anyone who tells you more than that is selling certainty they do not have.
Questions people ask
Was sermorelin approved by the FDA's advisory committee in July 2026?
No. The committee reviewed seven peptides at its July 23-24, 2026 meeting and sermorelin was not one of them. Any claim that it was approved or rejected there is wrong on the facts of the meeting.
So is sermorelin illegal?
The federal record we can check does not prohibit it, and it does not cover it either. It is not named in 21 CFR 216.23 and it is not in 503A category 1 or 2. What that means in practice depends on your state and on a licensed prescriber's judgement, which is why the state layer is the one to check next.
Why is sermorelin sold by clinics if it is not on the list?
The list governs what a compounding pharmacy may use under section 503A, and clinics are not the compounding pharmacy. A clinic can offer a consultation regardless. Whether a licensed pharmacy can fill a prescription for you is the question that matters, and it is answerable.
Does absence from category 2 mean it is safe?
No. Category 2 is a list of substances FDA has flagged as raising significant safety concerns; it is not a complete safety register, and absence from it is not a finding of safety. Safety for you is a clinical judgement made by someone who has examined you.
Finding licensed care
If you want to talk to someone who can evaluate your situation, start with a licensed clinic. We list clinics by city and publish what we checked about each one, with the verification date attached.
Sermorelin comes up most in the larger metros: Los Angeles, CA, Indianapolis, IN, Nashville, TN, Philadelphia, PA, San Diego, CA
Find licensed care All compound status guides
Sources checked October 25, 2026: FDA, Bulk Drug Substances Nominated for Use in Compounding Under Section 503A (document updated May 14, 2026); eCFR, 21 CFR 216.23; FDA Pharmacy Compounding Advisory Committee meeting record for July 23-24, 2026.